The 340B program is at a crossroads

Truzo is the compass to navigate 340B today,
tomorrow, and beyond

340B Compliance Challenges

Ensure integrity of 340B amidst growth and change

Seamlessly manage drug discount program overlap and address duplicate discounts regardless of the model.

$124.1B

Value of the 340B Drug Discount Program (2023)

16.5%

Increase from 2022

Schedule a Demo

Truzo 340B Benefits

Truzo is the truth zone for 340B compliance

From getting quality claims data from providers and identifying inappropriate MDRP requests to automating the good faith inquiry process or sending discount payments to covered entities, Truzo streamlines 340B management to ensure program integrity.

Harmonization of claims data with other programs to gain insights into purchasing trends
Configuration to meet manufacturer policies, including Contract Pharmacy management or claim submissions
Optionality to pay covered entities directly via a Direct Discount Model, whether today or in the future
Active covered entities Network participating in Good Faith Inquiries with our dedicated covered entities Support team

Webinar

Taking action amidst 340B uncertainty with Truzo

With ongoing 340B litigation, administrative shifts, and regulatory uncertainty, drug manufacturers face a complex and uncertain environment. At the same time, issues like program diversion and duplicate discounts continue to escalate, highlighting the need for better data quality and higher transparency. How can manufacturers regain control of these challenges as new models remain in limbo?

Watch On Demand